Immunomodulation of autoimmune diabetes by dendritic cells.
The biology and properties of dendritic cells (DCs) have been intensely studied in the research areas of infectious diseases, tumor immunology, and vaccine development. This unique subset of immune cells has recently also moved to the center of interest for basic and clinical research in autoimmunity, owing not only to the extraordinary importance of DCs in the initiation and sustenance of adaptive immune responses, but also to more recent discoveries about their profound ability to control and downregulate ongoing T-cell responses. We review current progress of using DCs in mice for induction and propagation of autoimmune T-cell responses and their therapeutic potential to dampen or even stop beta-cell-specific autoimmunity. Finally, we offer our perspective on how basic research progress in DC technology, mostly from mouse models, may translate into emerging diagnostic and therapeutic applications for human type 1 diabetes.
Pechhold
Klaus
K
NIDDK-Diabetes Branch, NIH, 10 Center Drive, Building 10-CRC, Room 5W-5888, Bethesda, MD 20892, USA. KlausP@intra.NIDDK.NIH.gov
Koczwara
Kerstin
K
D000818:Animals; D003713:Dendritic Cells / Q000502:physiology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D013601:T-Lymphocytes / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000502:physiology